Market Research Report
Global Systemic Scleroderma Treatment Market Size study, by Drug Class, and Regional Forecasts 2021-2027
|Published by||Bizwit Research & Consulting LLP||Product code||1019281|
Delivery time: 2-3 business days
|Global Systemic Scleroderma Treatment Market Size study, by Drug Class, and Regional Forecasts 2021-2027|
|Published: July 17, 2021||Content info:||
Global Systemic Scleroderma Treatment Market is valued approximately at USD 1.46 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 4% over the forecast period 2021-2027. Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs and occurs when immune system malfunctions and starts attacking body's own tissue and organs. Growing prevalence of systemic scleroderma is increasing the demand for therapies used to treat the symptoms and grant of supplemental approvals for existing treatment options along with the therapies that are under development are growing the demand in the market. For instance, in September 2020, U.S. FDA assigned, Orphan Drug Designation to Kadmon Holdings Inc. for its novel drug candidate, Belumosudil (KD025), which is developed for the treatment of systemic sclerosis. Similarly, in 2019, Boehringer Ingelheim International GmbH's product - Ofev (nintedanib) - got approval from U.S. FDA for treatment of patients with Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD). Furthermore, growing focus of biotechnology industries towards developing new therapies for the treatment of systemic scleroderma is expected to fuel the demand in coming years. However, lack of validated results and failure of clinical trials are expected to curb the growth during forecast period.
Among Asia Pacific, North America, Europe, Latin America, and Rest of the World, North America is the significant region across the world in terms of market share due to rising prevalence of systemic scleroderma in the region. Whereas Europe is anticipated to exhibit the highest growth rate over the forecast period 2021-2027, due to higher usage of generics and biosimilars for off-label systemic scleroderma therapy.
Major market player included in this report are:
Boehringer Ingelheim International GmbH
Gilead Sciences Inc.
Hoffmann La Roche Ltd.
Johnson & Johnson Services, Inc.
Eli Lilly and Company
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Phosphodiesterase 5 inhibitors - PHA
Endothelin Receptor Antagonists
Calcium Channel Blockers
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.
Target Audience of the Global Systemic Scleroderma Treatment Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers
List of figures